Bausch Health’s Phase 3 RED-C Program for Rifaximin SSD Misses Primary Endpoint in Cirrhosis-Related Hepatic Encephalopathy

Bausch Health’s Phase 3 RED-C Program for Rifaximin SSD Misses Primary Endpoint in Cirrhosis-Related Hepatic Encephalopathy

By, Admin 28 January 2026

Bausch Health Companies Inc. announced topline results from its global phase 3 RED-C clinical program evaluating amorphous-rifaximin solid soluble dispersion (SSD) for the primary prevention of hepatic encephalopathy (HE) in adults with liver cirrhosis.

Although rifaximin SSD was safe and well-tolerated, both phase 3 trials failed to meet the primary endpoint.

What the RED-C program studied?

The RED-C program consists of two large, global, randomized, double-blind, placebo-controlled phase 3 trials.

Key features:

  • More than 1,000 patients
  • 398 sites across 17 countries
  • Adults with liver cirrhosis
  • No prior episodes of hepatic encephalopathy
  • Evaluated rifaximin SSD for delaying the first HE episode

Company response

Thomas J. Appio, CEO, Bausch Health, said:

We are disappointed in the results, as there is currently no approved treatment for these patients. We are reviewing the full dataset to determine potential new development opportunities.

He also thanked patients, families, investigators, and research teams who participated in the studies.

Why this remains an unmet need?

Cirrhosis is a leading cause of end-stage liver disease in the United States. According to CDC data (October 25, 2024):

  • Chronic liver disease and cirrhosis rank ninth among causes of death

Progression of cirrhosis is often marked by:

  • Hepatic encephalopathy
  • Jaundice
  • Clinically significant ascites
  • Variceal haemorrhage

Currently, no therapies are approved for primary prevention of HE in cirrhosis patients without prior episodes.

What’s next?

Bausch Health says it remains committed to:

  • Hepatology research
  • Identifying potential new development paths based on the RED-C dataset
  • Advancing treatments across multiple therapeutic areas

Big picture

These results underscore how challenging it is to prevent first-onset hepatic encephalopathy. Even well-established molecules like rifaximin, when reformulated, face high clinical risk in this setting.

Future success may depend on:

  • Better patient stratification
  • Biomarker-driven enrollment
  • Combination strategies targeting gut microbiota, inflammation, and ammonia metabolism

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!